Adam Woodrow Sells 3,800 Shares of Paratek Pharmaceuticals, Inc. (PRTK) Stock

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) VP Adam Woodrow sold 3,800 shares of the firm’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total transaction of $89,604.00. Following the completion of the transaction, the vice president now directly owns 69,500 shares in the company, valued at $1,638,810. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Paratek Pharmaceuticals, Inc. (PRTK) traded down 1.279% during trading on Monday, hitting $23.545. 151,752 shares of the stock were exchanged. Paratek Pharmaceuticals, Inc. has a 1-year low of $9.80 and a 1-year high of $25.95. The firm’s market capitalization is $647.13 million. The company has a 50-day moving average price of $22.18 and a 200 day moving average price of $18.43.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($1.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.20) by $0.06. The business had revenue of $0.02 million during the quarter.

WARNING: “Adam Woodrow Sells 3,800 Shares of Paratek Pharmaceuticals, Inc. (PRTK) Stock” was originally posted by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.wkrb13.com/markets/2285555/adam-woodrow-sells-3800-shares-of-paratek-pharmaceuticals-inc-prtk-stock.html.

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, June 22nd. Raymond James Financial, Inc. assumed coverage on shares of Paratek Pharmaceuticals in a report on Thursday, May 18th. They issued a “strong-buy” rating and a $36.00 target price for the company. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 21st. HC Wainwright increased their target price on shares of Paratek Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. Finally, Guggenheim set a $38.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, April 4th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $37.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in Paratek Pharmaceuticals during the fourth quarter worth approximately $158,000. Falcon Point Capital LLC purchased a new position in Paratek Pharmaceuticals during the first quarter worth approximately $200,000. Russell Investments Group Ltd. purchased a new position in Paratek Pharmaceuticals during the first quarter worth approximately $211,000. American International Group Inc. increased its position in Paratek Pharmaceuticals by 34.1% in the first quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock worth $214,000 after buying an additional 2,824 shares in the last quarter. Finally, Nine Chapters Capital Management LLC purchased a new position in Paratek Pharmaceuticals during the first quarter worth approximately $258,000. Institutional investors and hedge funds own 75.43% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Insider Buying and Selling by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285555/adam-woodrow-sells-3800-shares-of-paratek-pharmaceuticals-inc-prtk-stock.html

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.